Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2001

View Archived Issues

AxyS describes new serine protease inhibitor design technology

Ascorbic acid enhances arsenic trioxide potency in MM cells

Replagal receives European approval for Fabry's disease

Graffinity Pharmaceutical Design and Biosearch Italia form drug discovery alliance

Data from Metformin GR phase II trial reported by DepoMed

Lexicon Genetics and Immunex enter drug target validation agreement

Novel imino sugar inhibits HBV DNA replication without affecting DNA polymerase function

Lorus Therapeutics expands Virulizin clinical trial for pancreatic cancer

MedImmune begins Vitaxin phase I trials for rheumatoid arthritis

Guanfacine improves tic disorders and ADHD in children

Baxter to acquire Asta Medica Oncology

Bayer withdraws cerivastatin worldwide

FDA approves PEG-Intron for use with Rebetol

Trimeris and Array Biopharma sign drug discovery agreement

Sustained-release preparations of hypoglycemic drugs described by Ajinomoto

BVdU reported to be useful for inhibiting the growth of hyperproliferative cells

Cyclin-dependent kinase inhibitors identified by Bristol-Myers Squibb

Kyowa Hakko patents new compounds for treatment of urinary incontinence

Smooth muscle-relaxing agents reported by Kissei

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...